Ignite Creation Date:
2024-05-06 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 2:14 PM
Study NCT ID:
NCT05067166
Status:
AVAILABLE
Last Update Posted:
2024-05-03
First Post:
2021-09-23
Brief Title:
Open-Label Expanded Access for Ebola-Infected Patients to Receive Human mAb Ansuvimab as Therapeutic or for HR PEP
Sponsor:
Ridgeback Biotherapeutics LP
Organization:
Ridgeback Biotherapeutics LP
Organization Data
Organization:
Ridgeback Biotherapeutics LP
Class:
INDUSTRY
Study ID:
Ansuvimab EAP-2020-DRC
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Ridgeback Biotherapeutics LP
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Institut National de Recherche Biomédicale Kinshasa République Démocratique du Congo | OTHER |